Megan Kelsey
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 44 | 2026 | 2623 | 4.380 |
Why?
| | Pediatric Obesity | 19 | 2026 | 635 | 3.990 |
Why?
| | Puberty | 12 | 2026 | 141 | 3.930 |
Why?
| | Insulin Resistance | 20 | 2026 | 1247 | 3.460 |
Why?
| | Bariatric Surgery | 10 | 2026 | 250 | 1.750 |
Why?
| | Hypoglycemic Agents | 10 | 2026 | 1412 | 1.520 |
Why?
| | Metformin | 7 | 2023 | 328 | 1.380 |
Why?
| | Obesity, Morbid | 9 | 2025 | 287 | 1.370 |
Why?
| | Adolescent | 69 | 2026 | 22557 | 1.370 |
Why?
| | Obesity | 18 | 2026 | 3131 | 1.270 |
Why?
| | Body Mass Index | 20 | 2026 | 2458 | 1.140 |
Why?
| | Prediabetic State | 6 | 2021 | 250 | 1.110 |
Why?
| | Blood Glucose | 17 | 2026 | 2360 | 1.060 |
Why?
| | Testosterone | 7 | 2024 | 419 | 0.990 |
Why?
| | Hypothalamic Diseases | 2 | 2026 | 17 | 0.950 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 393 | 0.910 |
Why?
| | Intra-Abdominal Fat | 2 | 2026 | 104 | 0.910 |
Why?
| | Child | 46 | 2026 | 22693 | 0.860 |
Why?
| | Adolescent Behavior | 3 | 2020 | 486 | 0.850 |
Why?
| | Health Behavior | 3 | 2020 | 802 | 0.800 |
Why?
| | Body Composition | 6 | 2026 | 689 | 0.780 |
Why?
| | Gastrectomy | 4 | 2026 | 164 | 0.740 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.710 |
Why?
| | Transgender Persons | 2 | 2024 | 213 | 0.640 |
Why?
| | Female | 64 | 2026 | 79499 | 0.620 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 2219 | 0.610 |
Why?
| | Anti-Obesity Agents | 3 | 2026 | 67 | 0.590 |
Why?
| | Humans | 82 | 2026 | 146342 | 0.580 |
Why?
| | Male | 53 | 2026 | 73396 | 0.570 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.550 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 143 | 0.540 |
Why?
| | Insulin | 7 | 2026 | 2525 | 0.540 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 191 | 0.520 |
Why?
| | Adipose Tissue | 3 | 2021 | 642 | 0.520 |
Why?
| | Fatty Liver | 3 | 2026 | 252 | 0.510 |
Why?
| | Receptor, Melanocortin, Type 4 | 3 | 2026 | 17 | 0.500 |
Why?
| | Body Weight | 1 | 2020 | 968 | 0.480 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 360 | 0.460 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1064 | 0.460 |
Why?
| | Depression | 4 | 2026 | 1575 | 0.430 |
Why?
| | Biomarkers | 5 | 2026 | 4340 | 0.410 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3930 | 0.410 |
Why?
| | Sex Factors | 4 | 2019 | 2107 | 0.400 |
Why?
| | Leptin | 1 | 2015 | 248 | 0.380 |
Why?
| | Muscle Fatigue | 1 | 2014 | 98 | 0.380 |
Why?
| | Muscle, Skeletal | 4 | 2026 | 1818 | 0.370 |
Why?
| | Thinness | 1 | 2013 | 100 | 0.370 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 203 | 0.370 |
Why?
| | Longitudinal Studies | 6 | 2026 | 3017 | 0.370 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5899 | 0.370 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1325 | 0.360 |
Why?
| | Disease Progression | 1 | 2020 | 2867 | 0.350 |
Why?
| | Off-Label Use | 2 | 2022 | 50 | 0.340 |
Why?
| | Mass Screening | 3 | 2022 | 1307 | 0.340 |
Why?
| | Risk Factors | 9 | 2026 | 10921 | 0.310 |
Why?
| | Cohort Studies | 8 | 2021 | 6077 | 0.300 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 364 | 0.300 |
Why?
| | Life Style | 4 | 2021 | 496 | 0.300 |
Why?
| | Diabetic Nephropathies | 2 | 2026 | 320 | 0.290 |
Why?
| | Androgens | 2 | 2022 | 179 | 0.290 |
Why?
| | Sleep | 3 | 2024 | 896 | 0.290 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 51 | 0.280 |
Why?
| | alpha-MSH | 2 | 2026 | 6 | 0.280 |
Why?
| | Reference Values | 2 | 2020 | 796 | 0.270 |
Why?
| | Ribonuclease III | 2 | 2021 | 44 | 0.260 |
Why?
| | Bone Density | 2 | 2023 | 494 | 0.260 |
Why?
| | Treatment Outcome | 12 | 2026 | 11821 | 0.260 |
Why?
| | Estradiol | 3 | 2022 | 517 | 0.260 |
Why?
| | Weight Gain | 2 | 2022 | 562 | 0.250 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 90 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2021 | 3647 | 0.240 |
Why?
| | Exercise | 4 | 2026 | 2213 | 0.240 |
Why?
| | Hunger | 1 | 2026 | 56 | 0.230 |
Why?
| | Fructosamine | 2 | 2016 | 11 | 0.230 |
Why?
| | Weight Loss | 7 | 2026 | 858 | 0.230 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 190 | 0.230 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.230 |
Why?
| | Adipokines | 1 | 2026 | 56 | 0.230 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 307 | 0.230 |
Why?
| | Deoxyglucose | 2 | 2016 | 51 | 0.230 |
Why?
| | Phentermine | 1 | 2025 | 14 | 0.220 |
Why?
| | Abdominal Fat | 1 | 2025 | 51 | 0.220 |
Why?
| | Serum Albumin | 2 | 2016 | 147 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 141 | 0.220 |
Why?
| | Young Adult | 11 | 2026 | 14330 | 0.210 |
Why?
| | Heart | 2 | 2025 | 626 | 0.210 |
Why?
| | Bacteria | 2 | 2020 | 766 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5439 | 0.200 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 73 | 0.200 |
Why?
| | Age Factors | 3 | 2021 | 3347 | 0.200 |
Why?
| | Endocrinology | 1 | 2024 | 77 | 0.200 |
Why?
| | Radius | 2 | 2023 | 53 | 0.200 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 199 | 0.200 |
Why?
| | Hypoglycemia | 2 | 2019 | 490 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 215 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1036 | 0.190 |
Why?
| | Aging | 1 | 2014 | 1996 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.180 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 769 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2026 | 2070 | 0.180 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 180 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1763 | 0.170 |
Why?
| | Colorado | 4 | 2020 | 4595 | 0.170 |
Why?
| | Mindfulness | 1 | 2024 | 134 | 0.170 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.170 |
Why?
| | Executive Function | 1 | 2026 | 463 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 5 | 2026 | 3926 | 0.170 |
Why?
| | Hypertension | 2 | 2021 | 1272 | 0.170 |
Why?
| | Obesity Management | 1 | 2021 | 12 | 0.170 |
Why?
| | Overnutrition | 1 | 2021 | 28 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2024 | 322 | 0.170 |
Why?
| | Blast Crisis | 1 | 2021 | 34 | 0.160 |
Why?
| | Adiposity | 2 | 2025 | 533 | 0.160 |
Why?
| | Hyperinsulinism | 1 | 2021 | 115 | 0.160 |
Why?
| | Time Factors | 4 | 2021 | 7109 | 0.160 |
Why?
| | Bacterial Typing Techniques | 1 | 2020 | 40 | 0.160 |
Why?
| | Hypogonadism | 1 | 2010 | 89 | 0.150 |
Why?
| | Bone and Bones | 1 | 2023 | 319 | 0.150 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 74 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 115 | 0.150 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.150 |
Why?
| | Linear Models | 2 | 2019 | 857 | 0.150 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 212 | 0.150 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 12 | 0.150 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 561 | 0.150 |
Why?
| | Growth Hormone | 1 | 2019 | 91 | 0.150 |
Why?
| | Sexual Maturation | 1 | 2019 | 49 | 0.150 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1135 | 0.150 |
Why?
| | Prognosis | 4 | 2021 | 4351 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 790 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 111 | 0.140 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 68 | 0.140 |
Why?
| | Research | 1 | 2022 | 421 | 0.140 |
Why?
| | Vascular Malformations | 1 | 2019 | 53 | 0.140 |
Why?
| | Dyslipidemias | 1 | 2021 | 184 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2019 | 1298 | 0.140 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 122 | 0.140 |
Why?
| | Capillaries | 1 | 2019 | 123 | 0.140 |
Why?
| | Hyperkalemia | 1 | 2009 | 35 | 0.140 |
Why?
| | Reproductive Health | 1 | 2019 | 94 | 0.140 |
Why?
| | Obstetric Labor Complications | 1 | 2018 | 38 | 0.140 |
Why?
| | Prospective Studies | 5 | 2021 | 8123 | 0.140 |
Why?
| | Pilot Projects | 2 | 2024 | 1888 | 0.140 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 86 | 0.130 |
Why?
| | Lacerations | 1 | 2018 | 38 | 0.130 |
Why?
| | Exome | 1 | 2019 | 233 | 0.130 |
Why?
| | Absorptiometry, Photon | 3 | 2026 | 278 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.130 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 140 | 0.130 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 80 | 0.130 |
Why?
| | Stress, Psychological | 1 | 2026 | 1171 | 0.130 |
Why?
| | Anal Canal | 1 | 2018 | 101 | 0.130 |
Why?
| | Algorithms | 2 | 2024 | 1849 | 0.130 |
Why?
| | Bacteremia | 1 | 2020 | 218 | 0.130 |
Why?
| | Diet | 2 | 2017 | 1273 | 0.130 |
Why?
| | Biodiversity | 1 | 2020 | 314 | 0.130 |
Why?
| | Adenoma | 1 | 2009 | 210 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2020 | 361 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 384 | 0.130 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 164 | 0.130 |
Why?
| | C-Peptide | 3 | 2026 | 191 | 0.120 |
Why?
| | Adult | 11 | 2026 | 41087 | 0.120 |
Why?
| | Overweight | 1 | 2022 | 614 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2025 | 17438 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 22 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2018 | 303 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 561 | 0.120 |
Why?
| | Triglycerides | 2 | 2020 | 527 | 0.110 |
Why?
| | Hyperglycemia | 2 | 2016 | 384 | 0.110 |
Why?
| | United States | 8 | 2022 | 16136 | 0.110 |
Why?
| | Adiponectin | 1 | 2016 | 243 | 0.110 |
Why?
| | Risk | 1 | 2017 | 920 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 7 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 665 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2019 | 801 | 0.100 |
Why?
| | Patient Education as Topic | 2 | 2018 | 770 | 0.100 |
Why?
| | Lipolysis | 1 | 2013 | 44 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.090 |
Why?
| | Observer Variation | 1 | 2014 | 356 | 0.090 |
Why?
| | Fasting | 1 | 2014 | 280 | 0.090 |
Why?
| | Nutrition Policy | 1 | 2013 | 56 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 154 | 0.090 |
Why?
| | Nutrition Assessment | 1 | 2013 | 90 | 0.090 |
Why?
| | Adolescent Health Services | 1 | 2013 | 74 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2018 | 692 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11913 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 190 | 0.090 |
Why?
| | Signal Transduction | 1 | 2026 | 5246 | 0.090 |
Why?
| | Pediatrics | 1 | 2020 | 1124 | 0.090 |
Why?
| | Electromyography | 1 | 2014 | 428 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 209 | 0.080 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1101 | 0.080 |
Why?
| | Muscle Contraction | 1 | 2014 | 438 | 0.080 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 265 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 7230 | 0.080 |
Why?
| | Potassium Channels | 1 | 2011 | 149 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 4093 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 874 | 0.080 |
Why?
| | Tibia | 2 | 2023 | 177 | 0.080 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1537 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 704 | 0.070 |
Why?
| | Motor Activity | 1 | 2013 | 704 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2021 | 3034 | 0.070 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Hyperpigmentation | 1 | 2026 | 26 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2026 | 170 | 0.060 |
Why?
| | Nausea | 1 | 2026 | 111 | 0.060 |
Why?
| | Ecological Momentary Assessment | 1 | 2026 | 50 | 0.060 |
Why?
| | Vomiting | 1 | 2026 | 131 | 0.060 |
Why?
| | Headache | 1 | 2026 | 150 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2025 | 151 | 0.060 |
Why?
| | Pro-Opiomelanocortin | 1 | 2024 | 20 | 0.050 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 84 | 0.050 |
Why?
| | Hyperphagia | 1 | 2024 | 37 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 150 | 0.050 |
Why?
| | Infant | 4 | 2021 | 10114 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2240 | 0.050 |
Why?
| | Liver | 2 | 2025 | 1864 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 558 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2936 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1665 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 417 | 0.040 |
Why?
| | Treatment Failure | 1 | 2023 | 361 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2024 | 721 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2488 | 0.040 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 8 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 2021 | 21 | 0.040 |
Why?
| | Bacteroidetes | 1 | 2021 | 20 | 0.040 |
Why?
| | Transferrin | 1 | 2021 | 48 | 0.040 |
Why?
| | Health Education | 1 | 2024 | 346 | 0.040 |
Why?
| | Animals | 3 | 2019 | 38107 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 308 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Blood Culture | 1 | 2020 | 27 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 142 | 0.040 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 143 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 68 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 2 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 7 | 0.040 |
Why?
| | Renin | 1 | 2009 | 33 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 22 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 58 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 83 | 0.040 |
Why?
| | Middle Aged | 4 | 2026 | 36619 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 148 | 0.040 |
Why?
| | Episiotomy | 1 | 2018 | 5 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 189 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 462 | 0.030 |
Why?
| | Wales | 1 | 2018 | 24 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 507 | 0.030 |
Why?
| | Perineum | 1 | 2018 | 36 | 0.030 |
Why?
| | Scotland | 1 | 2018 | 54 | 0.030 |
Why?
| | Potassium | 1 | 2009 | 151 | 0.030 |
Why?
| | England | 1 | 2018 | 106 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2009 | 138 | 0.030 |
Why?
| | Patient Care Bundles | 1 | 2018 | 30 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 522 | 0.030 |
Why?
| | Neoplasms | 1 | 2014 | 2954 | 0.030 |
Why?
| | Genotype | 1 | 2023 | 1879 | 0.030 |
Why?
| | Genetic Variation | 1 | 2023 | 996 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 496 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 997 | 0.030 |
Why?
| | Feces | 1 | 2021 | 496 | 0.030 |
Why?
| | Fecal Incontinence | 1 | 2018 | 90 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6460 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 974 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 237 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1177 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 525 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 738 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 88 | 0.030 |
Why?
| | Prenatal Care | 1 | 2018 | 310 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 335 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2092 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 745 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 667 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 881 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 194 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 587 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 478 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6073 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1734 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1707 | 0.020 |
Why?
| | Prevalence | 1 | 2021 | 2861 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2014 | 302 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 410 | 0.020 |
Why?
| | Aged | 2 | 2026 | 26432 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 174 | 0.020 |
Why?
| | Pedigree | 1 | 2014 | 512 | 0.020 |
Why?
| | RNA | 1 | 2009 | 926 | 0.020 |
Why?
| | Anthropometry | 1 | 2013 | 204 | 0.020 |
Why?
| | Fruit | 1 | 2013 | 144 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 159 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3125 | 0.020 |
Why?
| | Mice | 2 | 2019 | 18297 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 270 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 96 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 257 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 307 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 380 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 208 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1712 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 507 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1354 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 244 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 712 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1942 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3416 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3200 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 6034 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8391 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2991 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1394 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2921 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 787 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1500 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2786 | 0.010 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|